Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PLRX

Pliant Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PLRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2023)$-2.75

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:46 UTC.

What Pliant Therapeutics, Inc. does

Pliant Therapeutics, Inc. is a biopharmaceutical company engaged in the development of product candidates based on integrin-binding technology. The company focuses on creating therapeutics to address various diseases through its research and development efforts. Pliant operates in the research, development, and potential commercialization stage of the pharmaceutical industry, relying on collaborations and partnerships to advance its programs.

Summarized from Pliant Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2023)$-2.75
Debt/equity0.02

Revenue, margins & earnings

FY2021: net loss $97M on revenue $8M$8MFY2021FY2022: net loss $123M on revenue $10M$10MFY2022FY2023: net loss $161M on revenue $2M$2MFY2023
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Medical OfficerStock Option (Right to Buy)Award575,000—
  • 2026-07-13DirectorStock Option (Right to Buy)Award60,000—
  • 2026-07-13DirectorStock Option (Right to Buy)Award60,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Pliant Therapeutics, Inc. do?

Pliant Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as PLRX.

When did PLRX last file with the SEC?

Pliant Therapeutics, Inc.'s most recent SEC filing on record is a SCHEDULE 13G filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:46 UTC. This page is also available as JSON at /api/data?ticker=PLRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PLRX and 5,000+ tickers.

Create a free account — keep PLRX
For your agent
GET /api/data?ticker=PLRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt